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Abstract 
Prevalence of integrase inhibitor (INSTI) transmitted drug resistance (TDR) may increase with the 
increasing use of INSTIs. We analysed the prevalence of INSTI TDR in the Swiss HIV Cohort Study 
(2008-2014). In 1 of 1,316 (0.1%) drug-naïve samples a major INSTI TDR mutation was detected. 
Prevalence was stable although INSTIs were increasingly used. We showed that this is in contrast to 
the introduction of previous drug classes where more treatment failures with resistant strains 
occurred and TDR was observed more rapidly. We demonstrated on a population-level that it is 
possible to avoid TDR affecting a new drug class for years. 
 
 
 at E-Library Insel on M
ay 9, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
3 
 
Introduction 
Integrase strand transfer inhibitors (INSTIs) are increasingly prescribed to treat HIV-infected patients 
[1]. As INSTI-use and subsequent treatment failures increase, the number of transmitted INSTIs 
resistance is expected to increase in analogy to other drug classes [2, 3]. The risk of transmission of 
drug resistance is particularly high in populations where treatment-experienced patients are not on 
suppressive antiretroviral treatment (ART) [2]. 
Despite increasing use of INSTIs, transmission of INSTI resistance has not been widely reported [4, 5]. 
There are some anecdotal cases where the transmission of major INSTI drug resistance was reported 
[6, 7]. Minor resistance mutations are most likely polymorphic and occur more often in non-B 
subtype compared to subtype B infections [4, 5]. 
We aimed to analyze the prevalence of transmitted INSTI resistance in the Swiss HIV Cohort Study 
(SHCS) and to identify risk factors for its occurrence. In addition, we intended to specify the 
transmission potential for INSTI drug resistance in the SHCS population and to set it in historical 
context. 
 
Methods 
Study population 
We used data from the SHCS and the SHCS drug resistance database. The SHCS is an ongoing, 
nationwide, multicenter, clinic-based observational study [8]. The SHCS is highly representative and 
includes 85% of the newly infected patients and at least 75% of patients on antiretroviral treatment 
in Switzerland [2, 8]. Sequences from genotypic drug resistance tests (GRTs) are stored in a central 
database (SmartGene; Integrated Database Network System IDNS® version 3.6.14) [2]. Subtypes 
were defined using REGA HIV-1 Subtyping (V3.0) 
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(http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool#). If results returned 
inconclusive, the analysis was repeated with Comet subtyping (V1.0) (http://comet.retrovirology.lu/). 
The SHCS has been approved by the ethical committees of all participating institutions, and written 
informed consent has been obtained from all participants [8]. 
The SHCS drug resistance database contained 1,724 GRTs from the HIV-1 integrase gene, 1,168 were 
prospectively and 556 retrospectively sequenced. 1,521 of 1,724 GRTs were from INSTI-naïve 
patients and 1,057 of 1,724 from treatment-naïve patients. The retrospective sequencing was done 
systematically. All available samples from patients who were in the time period 2008-2011 newly 
diagnosed with HIV were sequenced as well as baseline samples of drug experienced patients who 
started INSTI-containing treatment and patients who failed on INSTIs. 
INSTI drug resistance 
To estimate the prevalence of transmitted INSTI resistance up to the year 2014, we included 1,316 
patients who had ≥1 GRT performed from the integrase gene before the first exposure to an INSTI 
(earliest GRT per patient chosen). Samples retrieved before 2008 were summarized in a group: 
≤2008. We considered drug resistance mutations listed by IAS-USA 2015 and differentiated between 
minor (T66AK, L74M, E92G, T97A, E138AK, G140AS, R263K) and major mutations (T66I, E92Q, F121Y, 
Y143CHR, S147G, Q148HKR, N155H) [9]. 
We performed a logistic regression adjusted for HIV subtype to quantify the impact of calendar year 
on transmitted INSTI resistance. 
To account for potential reversion of transmitted drug resistance mutations in the absence of drug 
pressure, we performed a sub-analysis including only GRTs from recently infected, treatment-naïve 
patients. A recent infection was defined as follows (details are described elsewhere [2]): acute HIV-1 
infection described by the physician, or documented seroconversion (<1 year between the last 
negative and first positive test), or an ambiguity score ≤0.5% combined with a CD4 cell count >200 
cells/µL [10]. 
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Transmission potential of drug resistance 
To estimate the transmission potential of INSTI drug resistance and to put our findings into a 
historical context, we compared different aspects of the time period after the introduction of INSTI 
(2008-2014) to the time periods after introduction of NNRTIs (1998-2004), unboosted PIs (1996-
2002) and ritonavir-boosted PIs (PI/r) (1999-2005). We differentiated unboosted PIs and PI/r because 
of the better potency of PIs/r. We compared the number of patients on the specific drug classes, the 
number of failures and the number of patients detected with ≥1 drug resistance mutation affecting 
the specific drug class. Additionally, we compared three different types of population viral load (PVL): 
1) PVL after first exposure to the specific drug class (after ≥120 days of continuous treatment), 2) PVL 
after treatment failure on a specific drug class, and 3) PVL after detection of the first major drug 
resistance mutation affecting the specific drug. To calculate the PVL, we summed the log10-
transformed viral loads from the respective patients. Each patient contributed to each year once. If a 
patient had ≥2 measurements within the same year, we calculated the mean of the log10-
transformed viral load. 
Treatment failure was defined as ≥1 viral load ≥500 HIV-1 RNA copies/mL (after 180 days of 
continuous treatment or previous viral suppression) followed by a treatment change or stop. 
Statistical analyses were performed with Stata SE Version 14.0 (StataCorp, College Station, TX).  
 
Results 
Transmission of INSTI resistance mutations 
INSTI resistance mutations were rarely detected among INSTI-naïve patients (Appendix 1). Only one 
major mutation was found (1 of 1,316, 0.1%). It was T66I, found in a sample retrieved in 2001. In 38 
of 1,316 (2.9%) samples viruses were found with minor INSTI resistance mutations. The most 
common minor mutations were L74M (17 of 1,316; 1.3%) and T97A (16 of 1,316; 1.2%). Minor 
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mutations were more common in subtype non-B compared to subtype B infections (24 of 466; 5.2% 
vs. 14 of 850; 1.6%; Fisher’s exact p-value <0.001). The detected minor mutations were most likely 
polymorphic. They were already present before (in 4 of 157 samples; 2.6%) the introduction of INSTIs 
in Switzerland (28 February 2008). We found no evidence for an increase in prevalence of minor 
mutations in the years after the introduction of INSTIs. The yearly prevalence was 2.4% (95% CI: 0.6-
5.9), 3.8% (1.4-8.2), 2.4% (0.8-5.4), 3.6% (1.8-6.6), 2.5% (0.8-5.8), 1.3% (0.2-4.7) and 3.9% (1.5-8.4) in 
2008 to 2014. The odds ratio (OR) per calendar year was 0.98 (95% CI: 0.8-1.2) when performing a 
logistic regression adjusted for HIV subtype B vs. non-B (OR: 3.3, 95% CI: 1.7-6.4, p=0.001). 
The results were similar when we restricted the analysis to recently infected patients. No major 
mutation was detected in 303 samples. Minor mutations tended to be more common in subtype 
non-B (4 of 92 samples, 4.4%) compared to subtype B infections (3 of 211 samples, 1.4%, p- =0.205).  
Potential reasons for the low prevalence of transmission  
The prevalence of transmitted INSTI mutations remained low, although the number of patients on 
INSTI was increasing from 259 in 2008 to 2,180 in 2014 (Appendix 2). The low prevalence may be 
explained by the low number of patients who were potential transmitters of INSTI resistance. 
Between 2008 and 2014, 85 patients failed an ART including INSTIs in the entire SHCS database. Fifty-
six of these 85 (61%) changed the treatment after a median of 49 days (IQR: 15-167) following 
treatment failure and a large proportion of these patients reached viral suppression (< 50 HIV-1 RNA 
copies/mL) later on (42 of 47 patients with a measurement, 89%).  
GRTs were performed in 54 of 85 (64%) patients failing INSTI treatments. In 26 (48%) of these GRTs 
INSTI mutations were found. The following major mutations were most commonly detected: N155H 
(n=18, 33%), Q148H (n=4, 7%), Y143C (n=4, 7%) and Y143R (n=3, 6%). In addition, 13 GRTs with drug 
resistant viruses were performed from samples of patients who had detectable viral load on an ART 
containing INSTI but did not fulfill our criteria for treatment failure. However, the majority of patients 
ever detected with a major INSTI drug resistance mutation were successfully (HIV-1 RNA  <50 
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copies/mL) treated at the last study visit (23 of 40, 58%), died (4 of 40, 10%) or stopped participating 
in the SHCS (8 of 40, 20%). Our findings reveal that only a very small number of patients are known to 
be potential transmitters of INSTI resistance mutations. 
Comparison to the introduction of other drug classes 
The transmission of drug resistance mutations against other drug classes was higher in the years 
following introduction [2]. An explanation for the difference is that the number of patients who failed 
on a treatment containing the other drug class was higher compared to the number of patients who 
failed on INSTI-treatments (Appendix 2). As mentioned above, in the first seven years after the 
introduction of INSTIs only 85 of 2,751 patients on INSTIs failed treatment. In the seven years after 
the introduction of unboosted PIs, PI/r and NNRTIs, 18.2 times (n=1,543 of 5,923), 5.7 times (n=482 
of 5,332) and 7.2 times (n=609 of 4,347) more patients failed the respective ART. The median PVL 
after first exposure to INSTIs, after failure on INSTI and after detection of INSTI resistance in the 
seven years after introduction of the first INSTI was much lower compared to the median PVL after 
introduction of other drug classes (Figure 1, Appendix 3 and 4). 
 
Discussion 
Seven years after introduction of INSTIs in Switzerland, no transmission of major INSTI resistance 
mutations was detected by our study. The major reason for this unexpected absence of INSTI 
transmission is most likely the very low transmission potential in the SHCS. Treatment-naïve patients 
had no transmission potential of INSTI resistance because of lacking INSTI resistance mutations and 
the number of treatment-failures on INSTI remained remarkably low. Thus, the PVL of patients who 
experienced a virological failure on INSTIs or who carried viruses with INSTI drug resistance 
mutations was very low. To put these findings in a historical context was even more impressive. The 
transmission potential of resistance mutations remained very low after the introduction of INSTI 
compared to the time after introduction of PIs and NNRTIs. 
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Despite these very encouraging and unexpected findings, the transmission of INSTI resistance most 
likely cannot be avoided in the long run [6, 7]. Boyd et al. postulated that it is only a matter of time 
until the prevalence of transmitted drug resistance affecting INSTIs is reaching higher levels. 
However, we demonstrated that the transmission of drug resistance affecting a new class can be 
minimized. The Swiss setting cannot be compared to other settings, e.g. with limited access to viral 
load monitoring or no available second-line and third-line therapies. In these settings, patients may 
stay longer on failing regimens and may accumulate more drug resistance mutations. These patients 
have not only a high transmission potential. They might also accumulate secondary mutations. Such 
strains might be transmitted and fixed in the population and might lead to major public health issues 
in the future [2]. 
Minor mutations were more frequently seen in non-B subtype infections but they probably do not 
have an impact on the treatment outcome as it has also been shown for minor PI mutations [11, 12]. 
The sample size was too small to analyze specific pattern among non-B subtypes. 
To our knowledge, this is the largest study assessing the transmission of INSTI drug resistance in a 
highly representative population. Due to the similar history of drug approval and treatment 
guidelines, our finding most likely also reflects the situation in other resource rich settings. 
Our study is limited by the fact that not all patients with a failure on INSTI had a GRT performed. This 
was partially due to the fact that drugs were switched at low viral loads, making resistance testing 
less successful [13]. Viral load measurements and genotypic drug resistance testing is routinely 
integrated in clinical care in Switzerland since 1997 and 2002, respectively, therefore the PVL, 
number failures and mutations might be slightly underestimated. But this issue does not alter our 
conclusions.  
To summarize, our study demonstrated that the transmission potential of drug resistance against a 
new drug class can be minimized in a setting coming very close to the World Health Organization 
target 90-90-90 [14, 15]. Nevertheless, it might only be a matter of time until the prevalence of 
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transmitted drug resistance affecting INSTI reaches notable levels. Of particular notice will be to 
investigate the effect of decreasing monitoring frequency that is proposed and performed in some 
countries. This may lead to delayed detection of treatment failures with subsequent emergence of 
resistance and a higher PVL of failing patients. From a global health perspective, it is important that 
the transmission potential in other settings can be minimized in a similar way. 
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Figure legends 
Figure 1: A-D) Population viral load (PVL) of patients treated with A) integrase strand transfer 
inhibitor (INSTI), B) non-nucleoside reverse transcriptase inhibitors (NNRTIs), C) unboostsed protease 
inhibitors (PIs) and D) ritonavir-boosted PI (PI/r) in the seven years after introduction of the drug 
class. The areas represent the PVL after first exposure to the specific drug class (light gray) and the 
PVL after virological failure on a specific drug class (dark gray).  
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